| Project/Area Number |
17K10540
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
Mimura Kosaku 福島県立医科大学, 医学部, 准教授 (90568031)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 乳癌 / 癌微小環境 / phospho-STAT1 / PD-L1 / HLA class I / CD8陽性T細胞 / 乳がん / 乳腺外科学 / 免疫細胞療法 |
|---|
| Outline of Final Research Achievements |
In the present study, we indicated that PD-L1 and HLA class I were co-expressed in phospho-STAT1, a molecule in the IFN-γ signaling pathway, positive breast cancer cells, and that phospho-STAT1 in breast cancer cells was activated by IFN-γ secreted from tumor infiltrating immune cells, and that phospho-STAT1 expression in breast cancer cells may be a potential biomarker for immunotherapy with anti-PD-1 monoclonal antibody.
|
| Academic Significance and Societal Importance of the Research Achievements |
近年、進行乳癌に対する新たな治療戦略の1つとして抗PD-1抗体を用いた免疫細胞療法が施行されている。しかし、その臨床効果は限られており、更なる治療の開発やバイオマーカーの開発などが必要と考えられている。乳癌微小環境におけるPD-L1の発現機構の１つを解明した本申請研究の成果は、進行乳癌症例おいて、抗PD-1抗体を用いた免疫細胞療法の効果増強方法やバイオマーカーの開発に寄与するものである。
|
